KPV: Lys-Pro-Val Tripeptide Research Profile

What Is KPV?

KPV is a synthetic tripeptide with the sequence Lysine-Proline-Valine (H-Lys-Pro-Val-OH). The three residues correspond to positions 11, 12, and 13 of α-melanocyte-stimulating hormone (α-MSH), the C-terminal end of the parent peptide. Public chemistry databases list the free-base form as C₁₆H₃₀N₄O₄, with a molar mass of about 342.44 g/mol, CAS number 67727-97-3, and PubChem CID 125672.^[5] Acetate-salt forms reported by some suppliers carry a slightly higher mass and a different elemental profile.

The interest in KPV comes from a simple research question: α-MSH itself has well-documented anti-inflammatory effects, but it also drives pigmentary signalling that complicates any attempt to use the full peptide as a clean anti-inflammatory tool. The Brzoska/Luger review in Endocrine Reviews describes KPV explicitly as a candidate that retains anti-inflammatory activity without the pigmentary action of intact α-MSH.^[3] That biological framing — small, stable, easier to synthesize, no MSH-style pigment effect — is most of the reason KPV stayed on the radar of inflammation-biology groups.

For a research reader, the practical takeaway is that KPV is best understood as a peptide-fragment tool compound rather than a drug. The literature gives clear preclinical signals to study; it does not give a finished clinical product.

Where KPV Sits in the α-MSH Story

α-MSH is a 13-amino-acid neuropeptide produced from proopiomelanocortin. Studies summarized in the Brzoska/Luger review describe it as broadly anti-inflammatory in preclinical models of dermatitis, vasculitis, ocular and gastrointestinal inflammation, fibrosis, and arthritis, with effects on NF-κB activation, adhesion-molecule expression, cytokine production, and IL-10 synthesis.^[3]

KPV represents the C-terminal tripeptide (α-MSH 11-13) of that hormone. In experimental work, this short fragment has retained a meaningful portion of the parent peptide's anti-inflammatory phenotype in vitro and in vivo while shedding the melanogenic effect that ties α-MSH to pigment-signalling pathways. That detachment is what investigators describe when they call KPV an "anti-inflammatory pharmacophore" of α-MSH.^[3]

It is worth being precise about what that does and does not mean. The detached fragment is biologically interesting because it suggests the anti-inflammatory action can be at least partially uncoupled from the pigmentary action. It is not the same thing as saying KPV is a fully validated anti-inflammatory drug. The fragment is a research tool whose translational value remains under-tested in late-stage trials.

Mechanism: NF-κB Suppression and PepT1 Uptake

The strongest single mechanistic study of KPV is Dalmasso et al. 2008 in Gastroenterology.^[1] Two findings from that paper anchor most of the modern mechanistic narrative around the tripeptide:

• NF-κB and MAP-kinase suppression at nanomolar concentrations. In Caco2-BBE and HT29-Cl.19A intestinal epithelial cells, and in Jurkat T cells, nanomolar KPV inhibited NF-κB luciferase reporter activity and MAP-kinase signalling in response to pro-inflammatory cytokine challenge, with downstream reduction of cytokine secretion.^[1]
• PepT1-mediated cellular uptake. Using cold KPV as a competitor for radiolabelled PepT1 substrate and [³H]KPV uptake kinetics, the same study showed that the tripeptide is transported into intestinal epithelial cells and immune cells via the H⁺-coupled di/tripeptide transporter PepT1. PepT1 expression is low in normal colon but increases in chronically inflamed colon, which the authors propose as one reason an oral KPV approach could become enriched at sites of intestinal inflammation.^[1]

Beyond the gut, melanocortin-system reviews describe KPV as also engaging classical α-MSH-associated anti-inflammatory pathways — IL-10 induction, reduced TNF-α, IL-1β and IL-6 signalling, and reduced leukocyte recruitment — in macrophage and mast-cell models.^[3][4] A 2025 keratinocyte study reported that KPV reduced fine-dust-induced oxidative stress and apoptosis through modulation of the MAPK/NF-κB pathway, which is consistent with the receptor-independent intracellular signalling picture rather than a clean single-receptor agonist story.^[6]

What this gives a research reader is a believable, multi-pathway mechanistic sketch rather than a one-line "KPV does X at receptor Y" claim. That nuance matters when interpreting downstream model data.

Preclinical Models: Colitis, Mast Cells, and Skin

Two complementary mouse-colitis papers do most of the in-vivo lifting for KPV.

1. PepT1-Mediated Anti-Inflammatory Effect (Dalmasso et al. 2008)

In addition to the in-vitro work above, Dalmasso et al. added KPV to drinking water in DSS- and TNBS-induced colitis in mice. The study reported reduced disease activity, lower histological scoring of inflammation, and lower colonic pro-inflammatory cytokine mRNA expression in KPV-treated animals.^[1]

2. Melanocortin-Derived Tripeptide in DSS and Transfer Colitis (Kannengiesser et al. 2008)

In Inflammatory Bowel Diseases, Kannengiesser et al. tested KPV in two IBD models: DSS-induced colitis and CD45RB^hi T-cell transfer colitis. KPV-treated DSS animals showed earlier recovery, stronger regain of body weight, reduced histological infiltrates, and lower myeloperoxidase activity. The transfer-colitis arm produced similar findings. Critically, when the experiment was repeated in mice carrying a nonfunctional melanocortin-1 receptor (MC1R^e/e), KPV still rescued the treated group from DSS-induced lethality.^[2]

The authors concluded that the tripeptide's anti-inflammatory effect appears at least partially independent of MC1R signalling, which fits the intracellular NF-κB and PepT1 picture from the Dalmasso work.^[2]

3. Skin and Keratinocyte Models

A more recent paper by Sung et al. (2025) in Tissue & Cell reported that Lys-Pro-Val reduced fine-dust-induced apoptosis and inflammation in keratinocytes by lowering oxidative stress and modulating MAPK/NF-κB signalling — a contemporary extension of the older α-MSH-tripeptide skin-inflammation literature.^[6]

The honest summary across these models is consistent. KPV shows a reproducible anti-inflammatory phenotype in mouse colitis and in cultured skin and immune cells. It is supported by multiple independent groups. It is also still preclinical.

KPV vs BPC-157 vs GHK-Cu — Where the Lanes Differ

Researchers often ask how KPV positions next to other short peptides circulating in inflammation and skin discussions. The honest answer is that the three most commonly compared compounds belong to different families and were investigated in different model systems. The table below summarizes that, without claiming clinical interchangeability.

None of these molecules is an approved therapeutic in the UAE or US, and none has a peptide-specific late-stage human-trial program of the kind seen with incretin agents. For research framing, the cleanest position is to keep KPV in the melanocortin-derived anti-inflammatory tripeptide lane, with BPC-157 in the recovery/repair-signalling lane and GHK-Cu in the skin/copper-remodelling lane. They are not substitutes for each other in a research-design sense. For format and handling, see the KPV research vial, BPC-157 research vial, and GHK-Cu research vial.

What the KPV Literature Does Not Yet Give You

Cautious reading of KPV requires acknowledging four real gaps:

• No registered Phase 2 or Phase 3 KPV trial. A clinicaltrials.gov search at the time of writing did not return a KPV-specific late-stage trial registration. Anyone framing KPV as a finished anti-inflammatory therapeutic is going beyond the published record.
• Receptor story remains layered. Kannengiesser et al. argue for MC1R-independent effects; Dalmasso et al. emphasize PepT1-mediated intracellular delivery and NF-κB suppression; reviews still acknowledge a melanocortin-related background. The literature is consistent with a multi-pathway mode of action, not a single receptor.^[1][2]
• Formulation, stability, and bioavailability questions. Most published KPV work uses cell culture, drinking-water dosing in rodents, or topical/transdermal formulations. Bioavailability after different administration routes, peptide stability in different vehicles, and dose-response curves at the human scale are not resolved in the public literature in the way they are for established protein medicines.
• Dose translation is unsupported. The published animal doses do not map cleanly to a human dose with any rigour, and this article makes no attempt to do so. Anyone offering specific "KPV protocols" for humans is going outside the published data.

These gaps are not arguments against studying KPV. They are arguments against overselling it.

Where KPV Fits in a Modern RUO Research Catalog

For a UAE-based research catalog operating under MoHAP Circular 17/2022, KPV belongs in the category of short anti-inflammatory peptide research tools — typically supplied as a 10mg lyophilized research vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work, and shipped with a per-batch Certificate of Analysis from an independent lab such as Janoshik. That format is consistent with how investigators have used the peptide in cell-culture and animal-model work in the published literature.

It is not framed for human use, not framed for veterinary use, and not framed as a treatment. The KPV research vial page documents the catalog format, batch-COA expectation, and handling notes; the wider catalog comparison sits at /products/, and the COA history sits in the COA library.

For researchers reading this page as a starting point, the most useful adjacent references on this site are the peptide primer, the bacteriostatic water guide, the stability and storage guide, and the Dubai legality brief. Researchers comparing KPV to other short peptides may also want the GHK-Cu copper-peptide review as a structural counterpoint.